Bortezomib: all 701 studies that test it

Page 1 of 8. Open to participants first (47), then studies with results posted, then the rest; newest registration first within each.

• CM336 Plus Isa-VR in Newly Diagnosed Primary Plasma Cell LeukemiaRecruitingNCT07652905Phase 2
• Acalabrutinib Maleate and Bortezomib for Patients With HLA AntibodiesNot yet recruitingNCT07635511Phase 3
• Study of Alternative and Approved Dosing Regimens of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Relapsed/Refractory Multiple MyelomaNot yet recruitingNCT07614360Phase 2
• A Study of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Multiple Myeloma and Moderate Hepatic ImpairmentNot yet recruitingNCT07609706Phase 1
• Isatuximab, Iberdomide, Bortezomib, Dexamethasone in Transplant Ineligible/Deferred Newly Diagnosed MyelomaNot yet recruitingNCT07601100Phase 1/2
• Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple MyelomaNot yet recruitingNCT07600151Phase 1/2
• Venetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic LymphomaRecruitingNCT07513129Phase 1
• Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null PhenotypeRecruitingNCT07341867Phase 1
• A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) AmyloidosisRecruitingNCT07224672Phase 2
• Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)Not yet recruitingNCT07072585Phase 2/3
• Fenofibrate Role in the Prophylaxis From Peripheral Neuropathy Induced by Bortezomib, Lenalidomide and Dexamethasone (VRd) Protocol in the Treatment of Patients With Multiple Myeloma (MM)RecruitingNCT07025005Phase 4
• Bortezomib Plus Cisplatin in Recurrent or Metastatic Breast CancerRecruitingNCT06900647Phase 1
• A Prospective, Single-Center Study Evaluating the Efficacy and Safety of Glofitamab Combined With Orelabrutinib and Bortezomib in Patients With High-Risk Mantle Cell LymphomaNot yet recruitingNCT06656221Phase 2
• Bortezomib Combined with PD-1 MAb and MFOLFIRINOX for Metastatic Pancreatic CancerRecruitingNCT06572813Phase 1/2
• Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)RecruitingNCT06390319Phase 2
• Bortezomib, Pomalidomide, Dexamethasone for Systemic AL AmyloidosisRecruitingNCT06342466Phase 2
• A Clinical Study on the Whole-course Management (BCD-KPD-AutoHSCT) Scheme for Patients With RIMMRecruitingNCT06203145Not applicable
• Optimize First-line Treatment for AL Amyloidosis With t (11; 14)RecruitingNCT06192979Not applicable
• Phase 2 Study Applying MRD Techniques for Participants With Previously Untreated Multiple Myeloma Treated With D-VRd Prior To and After High-dose Therapy Followed by ASCT - TAURUSRecruitingNCT06189833Phase 2
• A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)RecruitingNCT06083922Phase 2
• Bortezomib-based Regimen for Refractory or Relapsed Acute Lymphoblastic LeukemiaRecruitingNCT06034561Phase 2
• Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL AmyloidosisRecruitingNCT06022939Phase 3
• TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia IIRecruitingNCT05848687Phase 1/2
• Bortezomib for the Treatment of Refractory Rheumatoid ArthritisRecruitingNCT05805891Not applicable
• A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)RecruitingNCT05736419Phase 2
• GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5RecruitingNCT05695508Phase 2
• Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL)RecruitingNCT05681260Phase 3
• The Investigate Efficacy and Safety Evaluation of Bortezomib in Patients With Relapsed/Refractory Immune ThrombocytopeniaRecruitingNCT05599880Phase 2
• Selinexor Plus VRd in High Risk Newly Diagnosed Multiple MyelomaRecruitingNCT05422027Phase 1/2
• Post-Transplant Cyclophosphamide, Bortezomib and Abatacept for the Prevention of Graft-versus-Host-Disease (GvHD)RecruitingNCT05289167Phase 1/2
• Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM PatientsRecruitingNCT05272826Phase 2
• Chemotherapy Combined With Radiotherapy Versus Radiotherapy Alone for Solitary PlasmacytomaRecruitingNCT05248633Phase 2
• Efficacy and Safety of Bortezomib as First-line Treatment of Acquired TTPNot yet recruitingNCT05135442Phase 4
• Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients.RecruitingNCT04915248Phase 2
• Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE TrialRecruitingNCT04566328Phase 3
• A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.RecruitingNCT04414475Phase 2
• A Multicentre, Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home EnvironmentRecruitingNCT04268199Phase 2
• Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple Myeloma Patients With Renal InsufficiencyRecruitingNCT04240054Phase 2
• Trial to Evaluate Efficacy and Safety of Bortezomib in Patients With Severe Autoimmune EncephalitisRecruitingNCT03993262Phase 2
• HLA-Haploidentical Peripheral Blood Stem Cell Transplantation With Post-transplant Cyclophosphamide and BortezomibRecruitingNCT03850366Phase 2
• Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic DiseaseRecruitingNCT03844360Phase 4
• R-VRD Followed by Lenalidomide Maintenance in Patients With Waldenstrom's MacroglobulinemiaRecruitingNCT03697356Phase 2
• Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017RecruitingNCT03643276Phase 3
• VRD as Induction Followed by VR Maintenance in Patients With Newly Diagnosed High Risk Multiple MyelomaRecruitingNCT03641456Phase 2
• International Study for Treatment of High Risk Childhood Relapsed ALL 2010RecruitingNCT03590171Phase 2
• Childhood Acute Lymphoblastic Leukemia Treatment Protocol Moscow-Berlin 2015 (ALL-MB 2015)RecruitingNCT03390387Not applicable
• Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/LeukemiaRecruitingNCT03136146Phase 2
• A Study of Ibrutinib With Rituximab in Relapsed or Refractory Mantle Cell LymphomaCompletedNCT05564052Phase 2Results posted
• A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple MyelomaActive, not recruitingNCT04181827Phase 3Results posted
• High-Dose Post-Transplant Cyclophosphamide and Bortezomib (CyBor) for the Prevention of Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)CompletedNCT03945591Phase 2Results posted
• An Open-label, Dose Escalation Study in Japanese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma TreatmentsCompletedNCT03828292Phase 1Results posted
• To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Conjugate, GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or in Combination With Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)CompletedNCT03544281Phase 1/2Results posted
• Study of Melphalan Flufenamide (Melflufen) + Dex With Bortezomib or Daratumumab in Patients With RRMMTerminatedNCT03481556Phase 1/2Results posted
• Trial of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Bortezomib and LenalidomideTerminatedNCT03117361Phase 2Results posted
• Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple MyelomaCompletedNCT03110562Phase 3Results posted
• A Study to Evaluate Dara-CyBorD in Previously Untreated and Relapsed Subjects With Multiple MyelomaCompletedNCT02951819Phase 2Results posted
• Study of Ibrutinib in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed/Relapsed and Refractory Multiple MyelomaCompletedNCT02902965Phase 2Results posted
• Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant PatientsTerminatedNCT02877082Phase 2Results posted
• Exploratory Trial to Estimate Proportion of Patients With Tumor Cell Contaminated Leukapheresis Products With and Without Bortezomib With In-vivo Purging - Multiple Myeloma (MM)CompletedNCT02703779Phase 2Results posted
• Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple MyelomaCompletedNCT02654990Phase 2Results posted
• Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) IActive, not recruitingNCT02553460Phase 1/2Results posted
• A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple MyelomaCompletedNCT02541383Phase 3Results posted
• Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young AdultsTerminatedNCT02535806Phase 2Results posted
• Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or LymphomaTerminatedNCT02518750Phase 2Results posted
• Trial of High Dose Melphalan/Stem Cell Transplant With or Without BortezomibTerminatedNCT02489500Phase 3Results posted
• Clinical Trial of Expanded and Activated Autologous NK Cells to Treat Multiple MyelomaCompletedNCT02481934Phase 1Results posted
• Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple MyelomaCompletedNCT02441686Phase 2Results posted
• Optimising Renal Outcome in Myeloma Renal FailureCompletedNCT02424851Phase 2Results posted
• Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MMCompletedNCT02375555Phase 2Results posted
• Comparing and Combining Bortezomib and Mycophenolate in SSc Pulmonary FibrosisCompletedNCT02370693Phase 2Results posted
• Melphalan and Bortezomib Prior to Autologous Stem Cell Transplant in Treating Patients With Multiple MyelomaTerminatedNCT02353572Phase 1/2Results posted
• Bortezomib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Undergoing Stem Cell TransplantTerminatedNCT02353468Phase 2Results posted
• Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Japanese Patients With Relapsed/Refractory Multiple MyelomaCompletedNCT02290431Phase 2Results posted
• Safety/Efficacy Study of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or Relapsed/Refractory Multiple MyelomaTerminatedNCT02254551Phase 2Results posted
• Bendamustine Hydrochloride, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple MyelomaCompletedNCT02224729Phase 2Results posted
• Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)CompletedNCT02208037Phase 2Results posted
• Study of Difluoromethylornithine (DFMO) in Combination With Bortezomib for Relapsed or Refractory NeuroblastomaCompletedNCT02139397Phase 1/2Results posted
• Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic LymphomaActive, not recruitingNCT02112916Phase 3Results posted
• Study of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Patients With Multiple MyelomaCompletedNCT02100657Phase 1Results posted
• Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple MyelomaCompletedNCT02037256Not applicableResults posted
• Bortezomib to Treat Significant Complication of HSCTCompletedNCT01929980Phase 2Results posted
• Response Adapted Therapy With Bortezomib/Dexamethasone Followed by Addition of Lenalidomide in Non Responders as Initial Treatment for Patients With Multiple MyelomaCompletedNCT01919086Phase 2Results posted
• Bortezomib for Low or Intermediate-1 Myelodysplastic Syndrome (MDS) With p65 ActivationCompletedNCT01891968Phase 2Results posted
• Post-Transplant Bortezomib and High Dose Cyclophosphamide as Graft-Versus-Host Disease (GVHD) ProphylaxisCompletedNCT01860170Phase 1/2Results posted
• Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple MyelomaCompletedNCT01849783Phase 2Results posted
• Bortezomib in KRAS-Mutant Non-Small Cell Lung Cancer in Never Smokers or Those With KRAS G12DCompletedNCT01833143Phase 2Results posted
• WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell TransplantationCompletedNCT01827137Phase 1/2Results posted
• A Post-Approval Pharmacokinetic Study of Bortezomib in Participants With Multiple MyelomaCompletedNCT01801436Phase 3Results posted
• Lenalidomide/Bortezomib/Dexamethasone for Multiple Myeloma (MM)CompletedNCT01782963Phase 2Results posted
• Safety and Efficacy of Desensitization Therapy in Sensitized Participants Awaiting Heart TransplantationTerminatedNCT01769443Phase 2Results posted
• Bortezomib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic LeukemiaCompletedNCT01769209Phase 2Results posted
• Standard of Care vs. Bortezomib in Graft-Versus Host Disease After Hematopoietic Stem Cell TransplantCompletedNCT01754389Phase 2Results posted
• Bortezomib and Doxil for the Treatment of Patients With Acute Myelogenous LeukemiaCompletedNCT01736943Phase 2Results posted
• Velcade + Cyclophosphamide in Newly Diagnosed Multiple MyelomaTerminatedNCT01729338Phase 2Results posted
• Hemostatic Effects of VELCADE®* Treatment in Multiple Myeloma PatientsTerminatedNCT01720043Phase 2Results posted
• Subcutaneous (SC) Bortezomib-Regimens for Patients With RR MM Failing Prior IV Bortezomib-Containing RegimensTerminatedNCT01695330Phase 2Results posted
• A Trial of ASP7487 (OSI-906) in Combination With Bortezomib for the Treatment of Relapsed Multiple MyelomaTerminatedNCT01672736Phase 1/2Results posted
• Phase II Study of V-BEAM Conditioning Regimen Prior to Second Autologous Stem Cell TransplantationTerminatedNCT01653418Phase 2Results posted
• Busulfan, Melphalan, and Bortezomib Before First-Line Stem Cell Transplant in Treating Patients With Multiple MyelomaCompletedNCT01605032Phase 2Results posted
• Study of Tabalumab (LY2127399) in Japanese Participants With Relapsed or Refactory Multiple MyelomaCompletedNCT01556438Phase 1Results posted

← Bortezomib overview